| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | 1 | Y | 1 CC-486 + R-miniCHOP | 422 | 55 | 24 | 11 | 6 | 2 | 0 | 05/25/2021 | 187 | 71 |
| 2 R-miniCHOP | 56 | 28 | 14 | 9 | 5 | 0 | ||||||||
| 111 | 52 | 25 | 15 | 7 | 0 | |||||||||
| S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | 1 | Y | 0 CD19 CAR T-cell Therapy | 396 | 65 | 56 | 35 | 24 | 8 | 2 | 06/12/2023 | 124 | 40 | |
| 65 | 56 | 35 | 24 | 8 | 2 | |||||||||
| 2 | Y | 1 Mosunetuzumab | 3 | 3 | 1 | 1 | 1 | 1 | 06/12/2023 | |||||
| 2 Polatuzumab | 3 | 3 | 2 | 1 | 0 | 0 | ||||||||
| 3 Mosunetuzumab + Polatuzumab | 4 | 4 | 2 | 2 | 1 | 0 | ||||||||
| 4 Observation | 3 | 3 | 2 | 1 | 1 | 0 | ||||||||
| 13 | 13 | 7 | 5 | 3 | 1 | |||||||||
| S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | 1 | Y | 1 Tazemetostat (Arm 1) Dose Level 1 | 227 | 7 | 7 | 6 | 4 | 0 | 0 | 09/26/2023 | 96 | 33 | |
| 4 Zanubrutinib (Arm 3) Dose Level 1 | 10 | 10 | 6 | 0 | 0 | 0 | ||||||||
| 5 Zanubrutinib (Arm 3) Dose Level 2 | 4 | 4 | 4 | 4 | 4 | 1 | ||||||||
| 21 | 21 | 16 | 8 | 4 | 1 | |||||||||
| Yes | A051902-PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P | 1 | E | Total Registrations | 8 | 8 | 7 | 4 | 1 | 0 | 10/14/2023 | 168 | 71 | |
| 8 | 8 | 7 | 4 | 1 | 0 | |||||||||
| A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub | 1 | E | Total Registrations | 7 | 7 | 6 | 2 | 2 | 0 | 01/03/2024 | 198 | 73 | ||
| 7 | 7 | 6 | 2 | 2 | 0 | |||||||||
| 2 | E | Total Registrations | 1 | 1 | 0 | 0 | 0 | 0 | 01/03/2024 | |||||
| 1 | 1 | 0 | 0 | 0 | 0 | |||||||||
| AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy | 1 | E | Total Registrations | 20 | 20 | 8 | 3 | 1 | 1 | 08/15/2023 | 204 | 109 | ||
| 20 | 20 | 8 | 3 | 1 | 1 | |||||||||
| 2 | E | Total Registrations | 14 | 14 | 5 | 1 | 0 | 0 | 08/15/2023 | |||||
| 14 | 14 | 5 | 1 | 0 | 0 | |||||||||
| E4412-HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin | 1 | E | Total Registrations | 20 | 0 | 0 | 0 | 0 | 0 | 04/17/2019 | 103 | 56 | ||
| 20 | 0 | 0 | 0 | 0 | 0 | |||||||||
| EA4151-Lymph, AHCT +/-Ritux, MRD Neg | 0 | E | Total Registrations | 169 | 21 | 16 | 2 | 1 | 0 | 04/03/2018 | 231 | 81 | ||
| 169 | 21 | 16 | 2 | 1 | 0 | |||||||||
| 1 | E | Total Registrations | 133 | 18 | 13 | 5 | 2 | 1 | 04/03/2018 | |||||
| 133 | 18 | 13 | 5 | 2 | 1 | |||||||||
| No | ANHL1931-PMBCL, Chemo-Immunotherapy +/- Nivo | 1 | E | Total Registrations | 22 | 12 | 7 | 2 | 0 | 0 | 02/28/2022 | 229 | 107 | |
| 22 | 12 | 7 | 2 | 0 | 0 | |||||||||
| Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|
| S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | 3 Crossover | 23-Feb-23 | 124 | 40 |